EULAR 2006

skip to the content

MabThera Rituximab – B Cell Therapy, Lasting Success

EULAR 2006 Media Kit

Press Release

New evidence shows MabThera (rituximab) inhibits joint damage

Backgrounders

Rituximab in rheumatoid arthritis
Highlights of rituximab data being presented at EULAR 2006

Promising future ahead for Roche in rheumatoid arthritis

Rheumatoid arthritis

B cell events at a glance

Role of B cells mechanism of action animation

Edited MOA highlights for broadcast

Image library featuring: diagnosis and symptoms, joint effects, lifestyle, role of B cells and rituximab MOA

B-roll request form

Journalists’ Roundtable Meeting

Legal Statement
Sitemap
Privacy Policy
Roche.com
© 2009 F. Hoffmann-La Roche Ltd. The site is intended for non US physicians and scientific media only.Prescribing information, pricing and indications for MabThera may differ from country to country.Please consult your local Roche company for such information you may be interested in.